340B Drug Pricing Program
AHA 340B Advocacy Alliance Member Only Webinar September 16, 2020
Improving the health of their communities is at the heart of every hospital’s mission. As one example, in a new analysis released, the American Hospital Association (AHA) found that 340B tax-exempt hospitals provided more than $64.3 billion in total benefits to their communities in 2017 alone, the…
Improving the health of their communities is at the heart of every hospital’s mission. Tax-exempt hospitals are required to publicly report on the ways in which they improve the health of the communities they serve yearly through the IRS Form 990 Schedule H, which is publicly available.
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana DeGette, D-Colo., and David McKinley, R-W.Va., along with Reps. Peter Welch, D-Vt., Greg Gianforte, R-Mont., Dusty Johnson, R-S.D., and…
The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to hospitals.
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
Statement on the FY 2021 final IPPS rule from AHA Senior Vice President for Public Policy Analysis and Development Ashley Thompson.
The AHA and other national health care groups urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable communities they serve “from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other…
On behalf of the nation’s 340B hospitals, AHA, others urge HHS to protect vulnerable communities from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other health care services.
The AHA sent letters to the heads of U.S. operations for five large drug companies — Merck, Eli Lilly, Sanofi, Novartis and AstraZeneca — expressing “profound concern” over actions they are taking to limit the distribution of certain 340B drugs to hospitals and health systems and asking them to “…